Categories: Drug Research

Aurobindo Pharma receives final approvals for Nafcillin Injections

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin for Injection USP, packaged in 1g and 2g vials (ANDA 091613) and  Nafcillin for Injection USP 10g/Vial Pharmacy Bulk Package (ANDA 091614). The products are ready for launch. Nafcillin for Injection is a sterile semisynthetic  penicillin (SSP) indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It may be used to initiate therapy in  suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results.

These ANDAs have been approved out of Unit XII formulation facility in Hyderabad, India and will be marketed and sold by Aurobindo’s US subsidiary AuroMedics Pharma LLC Aurobindo now has a total of 171 ANDA approvals (145 Final approvals including 2 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA

The Pharma Times News Bureau

Recent Posts

Kaivalyadhama to Host 11th International Conference on Yoga in Cancer Care, Uniting Global Experts to Explore Yoga’s Role in Holistic Cancer Support

Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…

18 hours ago

Sringeri Sharada Equitas Hospital Revolutionizing Cancer Care with the Launch of Low-cost, High Quality Radiation Therapy

The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…

18 hours ago

From Pain to Relief: How endoscopic spine surgery enhances patient outcomes

By DR UMESH SRIKANTHA, Senior Consultant - Neurosurgery, Head of Spine Services, Aster RV Hospital …

2 days ago

Henkel India Unveils Dedicated Researchers’ World Lab in India

Pune, November 11, 2024: Henkel Adhesives Technologies India Private Limited (Henkel India) announces the opening…

2 days ago

Esaote Group Expands Production in India

Noida, November 08, 2024: Esaote Group, a leading Italian innovator in medical imaging - ultrasound,…

5 days ago

In Q2 FY25, AGI Greenpac Limited posts EBITDA of ₹166 crore up by 20% Y-o-Y and PAT of Rs ₹72 crore up by 28%

Gurugram, November 08, 2024: AGI Greenpac Limited, a focused Packaging Products company, today announced its financial…

5 days ago